Table 2 Primary study outcomes .... | American Society of Hematology

Table 2

Primary study outcomes

	Argatroban/danaparoid n/N (%)	Fondaparinux n/N (%)	P*
Primary efficacy outcome†
Unmatched cohort	21/106 (19.8)	22/133 (16.5)	.392
Matched cohort	13/60 (21.4)	22/133 (16.5)	.424
Primary safety outcome‡
Unmatched cohort	27/106 (25.5)	28/133 (21.1)	.420
Matched cohort	12/60 (20.0)	28/133 (21.1)	.867

	Argatroban/danaparoid n/N (%)	Fondaparinux n/N (%)	P*
Primary efficacy outcome†
Unmatched cohort	21/106 (19.8)	22/133 (16.5)	.392
Matched cohort	13/60 (21.4)	22/133 (16.5)	.424
Primary safety outcome‡
Unmatched cohort	27/106 (25.5)	28/133 (21.1)	.420
Matched cohort	12/60 (20.0)	28/133 (21.1)	.867

χ² or Fisher’s exact test.

Thrombosis and thrombosis-related mortality during nonheparin anticoagulation.

Bleeding and bleeding-related mortality during nonheparin anticoagulation.